Tobacco smoking treatment results related to protease inhibitor PIM phenotype subtypes

M. Gambaryan, N. Didkovsky, A. Kalinina, A. Deev (Moscow, Russian Federation)

Source: Annual Congress 2005 - What's new in tobacco and lung disease
Session: What's new in tobacco and lung disease
Session type: Oral Presentation
Number: 3058
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Gambaryan, N. Didkovsky, A. Kalinina, A. Deev (Moscow, Russian Federation). Tobacco smoking treatment results related to protease inhibitor PIM phenotype subtypes. Eur Respir J 2005; 26: Suppl. 49, 3058

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Susceptibility to tobacco smoke related to protease inhibitor PIM subtypes in COPD
Source: Annual Congress 2005 - What's new in tobacco and lung disease
Year: 2005


A combination of erythromycin and dexamethasone reduces inflammatory effects of exposure to cigarette smoke extract through modulation of Akt and histone deacetylase 2
Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases
Year: 2014


Inhibition of lung inflammation by a protein epitope mimetic (PEM) neutrophil elastase inhibitor, POL6014, in a sub-chronic tobacco smoke (TS) model in mice
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013


Increased proportion of slow decliners in patients with alpha-1 protease inhibitor (A1-PI) deficiency following treatment with A1-PI
Source: International Congress 2016 – New and old therapies for chronic lung diseases
Year: 2016


LSC Abstract – A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection
Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects
Year: 2015

A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection
Source: Lung Science Conference 2015
Year: 2015

A selective MMP-12 inhibitor, MV062926, reduces inflammatory responses to cigarette smoke in mice
Source: Annual Congress 2010 - Pre-clinical models of airways disease
Year: 2010



Increased detection of interleukin-;5 in sputum by addition of protease inhibitors
Source: Eur Respir J 2001; 18: 685-691
Year: 2001



The combination of TNF-α neutralization and dexamethasone treatment restored the corticosteroid responsiveness in tobacco smoking mice
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016

Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice
Source: Eur Respir J 2006; 27: 1102-1109
Year: 2006



Potent anti-inflammatory effects of the highly selective iNOS inhibitor Byk402750 in a mouse model of cigarette smoke induced inflammation
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD
Year: 2008

Ensifentrine, a dual PDE3/PDE4 inhibitor, improves FEV1 regardless of smoking status or history of chronic bronchitis
Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases
Year: 2020




BmTI-A, a serine protease inhibitor, reduces the chronic allergic lung inflammation in a mice model
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015

Therapeutic neutralization of the matrikine PGP suppresses the development of lung emphysema in cigarette smoke exposed mice
Source: International Congress 2016 – Mechanisms of disease
Year: 2016

Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015


Macrophage chromatin condition and protease inhibitor activity studying in brush-biopsies at patients with infectious COPD exacerbation
Source: Eur Respir J 2007; 30: Suppl. 51, 142s
Year: 2007

Impact of polymorphisms in genes involved in nicotine dependence pathways on the smoking burden of COPD patients
Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency
Year: 2019


COPD non-exacerbator phenotype is associated with current smoking but not with Haptoglobin phenotype
Source: International Congress 2017 – Airway disease and exacerbations
Year: 2017

Women and lung cancer: potential mechanisms of greater susceptibility to tobacco smoke
Source: ISSN=1025-448x, ISBN=1-904097-28-6, page=146
Year: 2003

Human airway trypsin-like protease stimulates protease activated receptors and interactions of these receptors
Source: International Congress 2019 – Immunopathological mechanisms of lung disease
Year: 2019